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Human enterovirus 71 (EV71) has emerged as a neuroinvasive virus that is responsible for several outbreaks in
the Asia-Pacific region over the past 15 years. Appropriate animal models are needed to understand EV71
neuropathogenesis better and to facilitate the development of effective vaccines and drugs. Non-human primate
models have been used to characterize and evaluate the neurovirulence of EV71 after the early outbreaks in late
1990s. However, these models were not suitable for assessing the neurovirulence level of the virus and were
associated with ethical and economic difficulties in terms of broad application. Several strategies have been applied to
develop mouse models of EV71 infection, including strategies that employ virus adaption and immunodeficient hosts.
Although these mouse models do not closely mimic human disease, they have been applied to determine the
pathogenesis of and treatment and prevention of the disease. EV71 receptor-transgenic mouse models have recently
been developed and have significantly advanced our understanding of the biological features of the virus and the
host-parasite interactions. Overall, each of these models has advantages and disadvantages, and these models are
differentially suited for studies of EV71 pathogenesis and/or the pre-clinical testing of antiviral drugs and vaccines. In
this paper, we review the characteristics, applications and limitation of these EV71 animal models, including non-human
primate and mouse models.
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Introduction
Since the effective control of poliovirus, enterovirus 71
(EV71) has been regarded as the most important neuro-
tropic enterovirus. EV71 belongs to the species Human
enterovirus A of the genus Enterovirus within the family
Picornaviridae and is the major pathogen of hand-foot-
mouth disease (HFMD). EV71 was first described in
1974 after it was isolated from patients in California and
from then on, EV71 infection has been reported in at
least 12 small and large outbreaks throughout the world
[1-4]. Two subsequent outbreaks occurred in Malaysia
and Taiwan in the late 1990s, and these outbreaks mainly
affected young children and were characteristically associ-
ated with severe neurological complications and high rates* Correspondence: dckyu@mail.ncku.edu.tw
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unless otherwise stated.of fatality [3,5]. Since then, the Asia-Pacific region, in-
cluding Taiwan, Malaysia, Vietnam, Singapore, Japan and
China, has experienced more frequent large-scale EV71-
associated HFMD epidemics.
EV71 infection is generally mild and self-limited, but
occasionally such infection leads to central nervous sys-
tem (CNS) infections that include aseptic meningitis,
brainstem encephalitis and acute flaccid paralysis [6,7].
Fatal EV71 cases develop and progress rapidly and are
typically associated with neural complications, pulmon-
ary edema and function collapse, which make clinical
management challenging [8,9]. The precise mechanisms
of EV71-mediate disease, particularly the neuropatho-
genesis, are still not fully understood because suitable
and relevant animal models have not been established.
Similar to poliovirus, EV71 has a limited host range;
humans are the only known natural host. Early studies
showed that the members of Picornaviridae display distinct
pathogenicities in newborn mice for which neither polio-
virus nor echovirus are pathogenic; coxsackie A viruses
were found to cause generalized myositis, and coxsackie Bl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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after the discovery of EV71, experimental EV71 infections
were reported in neonatal mice [12,13] and cynomolgus
monkeys [14]. However, EV71 experimental infection
models were not established until the severe outbreaks in
the Asia-Pacific region around the late 1990s [6,15].
Experimental models of EV71 infection, including mur-
ine and non-human primate models, have been developed
as alternative means to determine the pathogenesis of and
treatments and preventions for the diseases caused by this
virus. Indeed, works based on these models have advanced
our knowledge of EV71 infection and disease, and most
importantly, have accelerated the development of EV71
vaccines. In this review, we discuss these animal models
and emphasize their applications and limitations (summa-
rized in Table 1).
Clinical features of EV71 infection in humans
Like other types of enteroviral infections, EV71 infection
may cause persistent fever, diarrhea, rashes, aseptic men-
ingitis and encephalitis, usually without life-threatening
manifestations [3,16]. The majority of infected children
have asymptomatic and self-limiting infections. Mild cases
are characterized by upper respiratory tract infection and
cutaneous diseases such as HFMD and herpangina. The
illness is characterized by 3–4 days of fever and the devel-
opment of a vesicular enanthem on the hands, feet and
buttocks and herpangina that involves popular lesions on
the mucosa of the anterior pillars of Fauces [7]. However,
potentially life-threatening neurological and systemic
complications, such as brain stem encephalitis, acute
flaccid paralysis, autonomic nervous system dysregula-
tion and pulmonary edema, are of the greatest clinical
and public concern [3,17-20].
Animal models used for the study of EV71 tropism and
pathogenesis
a. Non-human primate models
Early studies showed that non-human primates, includ-
ing cynomolgus, rhesus and green monkeys, are suscep-
tible to EV71 infection [12,14,21]. Non-human primate
models have been used to evaluate and characterize the
neurovirulence of EV71 since the outbreaks of the late
1990s. Similar to the neurological manifestations in
humans, cynomolgus monkeys display both pyramidal
tract signs (flaccid paralysis) and extrapyramidal tract
signs (including tremor and ataxia) with a broad viral
antigen distribution that involves the spinal cord, brain-
stem, cerebellar cortex, dentate nuclei and cerebrum
following intraspinal and intravenous inoculation of
EV71 [22,23]. The neuropathological features are highly
consistent with those observed in humans with severe
EV71 encephalitis at autopsy [5,18,24-26], which is indi-
cative of the similarity of the susceptibilities of humanand cynomolgus monkey CNS tissues to EV71. EV71 ex-
hibits a wider neurotropism than does poliovirus in cyno-
molgus monkeys, and wild-type strains, including those
isolated from patients with fatal encephalitis or hand, foot,
and mouth disease (HFMD), exhibit no marked differ-
ences with respect to neurovirulence after infection; thus,
this monkey species may not be suitable for assessing the
neurovirulence level of the virus [22,23]. Additionally, the
clinical manifestations in cynomolgus monkeys are not
correlated with those in patients. The monkeys do not
manifest cutaneous lesions or develop pulmonary edema,
although they have brainstem lesions [22,23]. Pulmonary
edema has been reported to be frequently associated with
fatal EV71 infection in children and is considered to be re-
lated to the damage to the brainstem [4,5,27,28].
Cynomolgus monkeys have been used to identify the
molecular determinants of EV71. EV71 mutant strains
derived from the prototype BrCr strain, which contains
mutations in the 5′ non-translated region (NTR), 3D
polymerase and 3′ NTR, exhibit attenuated neuroviru-
lence with a limited viral spread in the CNSs of mon-
keys [29]. Furthermore, this attenuated EV71 strain may
be an effective vaccine as it is able to induce a broad
spectrum of neutralizing antibody responses against differ-
ent genotypes of EV71 [30].
Zhang et al. [31] reported another non-human primate
model involving adult rhesus monkeys. After inoculation
with an EV71 clinical isolate (EV71/FY-23) intracerebrally,
intravenously, orally (in drinking water) or intratracheally,
monkeys develop CNS infections and neuronal impair-
ment with extra-neuronal pathological changes that are
confined to the lung tissues (i.e., cellular infiltration and
tissue damage) and are not present in the pancreas and
spleen where high viral loads are detected. Additionally,
the infected-animals do not develop vesicular lesions on
the skin and exhibit neither reduced muscle tension in the
limbs nor typical neurological symptoms. These results
suggest that, in addition to neurotropism, EV71 also elicits
respiratory tract tropism in rhesus monkeys; these obser-
vations contrast with those based on cynomolgus mon-
keys and mice. This adult rhesus monkey model presents
with all of the infectious and pathogenic processes of a
systemic EV71 infection and reveals the clinical mani-
festations, kinetics of viremia, viral loads in the neur-
onal and extra-neuronal tissues, immune responses and
histopathological changes. Interestingly, intracerebral in-
oculation induces pulmonary edema and hemorrhages
around the hilum of the lung in half of the monkeys. Al-
though it is not known whether the pulmonary edema
results from a viral cytolytic effect in the lungs or is a con-
sequence of CNS damage and inflammatory reactions, this
adult rhesus monkey model is the first system to show
that human EV71 can induce pulmonary edema in a non-
natural host.
Table 1 Enterovirus 71 animal models for pathogenesis studies




Cynomolgus monkey Clinical isolates and
prototype BrCr
i.s./106 CCID50 The monkeys developed neurological
manifestations including both pyramidal and
extrapyramidal tract signs, such as flaccid
paralysis, tremor and ataxia. The virus
replicated in the spinal cord, brainstem,
cerebella and cerebrum. EV71 had a wider
neurotropism than that of polioviruses.
19,20,27,28





i.c., i.v./106.5 CCID50 The infected adult monkeys developed CNS
infection and neuron impairment with
extra-neuronal pathological changes confined
to the lung tissues and not the pancreas and
spleen, where high viral loads were detected.
2,29,30
i.t./ 104.5 CCID50 In neonate monkeys, HFMD-liked papules and
vesicles were found on the limbs and in the
mouth after intratracheal infection. However,
the typical neurological complication was not
observed. High viral titers were transiently




ICR, 1- to 14-day-old Mouse-adapted EV71 strain
(MP4, C2 genotype)
oral/5 × 106 pfu The mice developed rear limb paralysis (with
massive and widespread necrotizing myositis)
and neuropathologies (with neuronal loss and
apoptosis) in the spinal cord and brainstem
before death. The spinal cord, brain and
muscle were the major organs for virus
replication in the late phase of infection.
Retrograde axonal transport in neurons might
represent the major transmission route of
EV71 in mice.
7,13,36,38,39
i.m./5 × 103 pfu
i.c./5 × 104 pfu
BALB/c, 1- to 7-day-old Mouse-adapted strain
(MP-26 M)
i.c. /3.4 × 104 TCID50 The mice developed limb paralysis followed
by death after MP-26 M infection. Skeletal
muscle displayed severe necrotizing myositis
and contained a high viral load. Viruses were
also isolated from the blood, hearts, livers,
spleens and brains of infected mice. The VP1
mutation (G145E) alone was sufficient to increase
the virulence of the virus in mice.
33
i.m./3.4 × 103 TCID50
i.p./3.4 × 104 TCID50
ICR, 2-week-old Mouse-adapted strain
(MAVs, B3 genotype)
i.c., i.p., s.c., oral/105
CCID50
The mice developed paralysis followed by
death after i.c., i.p., s.c. and i.m. administration
but not after oral inoculation of the virus.
The highest viral titers were detected in
the skeletal muscle, spleen and spinal cord.
The virus might enter the CNS via peripheral
motor nerves after skeletal muscle infection.
37
i.m./3 × 105 CCID50
ICR, 1-day-old Mouse muscle-adapted strain
(Fuyang-0805a, C4 genotype)
i.p./105 TCID50 The Fuyang-0805a strain showed strong
myotropism and induced severe necrotizing
myositis in both skeletal and cardiac muscles.





3- to 4-week old
NOD/SCID mouse-adapted strain i.c./106 CCID50 The infected mice showed paralysis of the
hind limbs. Viral RNA was first detected in the
CNS and serum and then high copy numbers




AG129, 10-week-old A129 and AG129 mouse-adapted
strain (B2 genotype)
i.p./5.2 × 104 TCID50 The infected AG129 mice but not A129 mice
developed limb paralysis, eye irritation, loss of
balance and control of movements and
exhibited high mortality.
43
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Table 1 Enterovirus 71 animal models for pathogenesis studies (Continued)
AG129, 2-week-old Clinical isolate
(5865/SIN/00009, B4 genotype)
i.p./106 pfu The infected mice displayed progressive limb
paralysis before death. The virus accumulated in
the CNS and resulted in massive damage in the
limb muscles, brainstem and anterior horn of
spinal cord. Low viral particles in the limbs after
oral inoculation indicated that the paralysis was
a consequence of EV71 neuroinvasion.
32
oral/107 pfu
Gerbils, 21-day-old Clinical isolate
(EV71/58301, C4 genotype)
i.p./105 TCID50 The infected animals developed neurological
disorders such as hind limb paralysis,
slowness, and ataxia before death.
Significantly high viral titers were detected in
the spinal cord, brainstem and skeletal muscle.
44
Transgenic mice
PSGL-1, 10-day-old Clinical isolates C4 genotype and
Mouse muscle-adapted strain
(Fuyang-0805a, C4 genotype)
i.p./108 TCID50 The transgenic mice were only susceptible to
a mouse muscle-adapted EV71 strain and not
the EV71 clinical isolates and exhibited severe
symptoms that were comparable to those of
the wild-type mice upon EV71 infection. High
viral titers were detected in the muscle, spinal
cord and brain after mouse-adapted virus
infection. This study concluded that human
PSGL-1 alone was not sufficient to provoke
the infectivity of EV71 in mice.
50
SCARB2, 1- to 14-day-old Clinical isolates, C2, C4, B4 and
B5 genotypes and CA16
s.c./3 × 104 to 106 pfu EV71 B genotypes were capable of inducing
HFMD-like lesions and neurological disease
with limb paralysis in 1-day-old but not
transgenic mice older than 2 weeks of age. In
contrast, 7- and 14-day-old but not 21-day-old
transgenic mice were more susceptible to the
C genotypes of EV71 and coxsackievirus A16
and exhibited more severe CNS diseases, limb
paralysis and death than did the non-
transgenic mice.
52
SCARB2, 3-week-old Clinical isolates (Isehara/Japan/99,
C genotype)
i.c., i.v., i.p., oral/ 104 to
106 TCID50
The transgenic mice displayed ataxia, paralysis
and death. The CNS, including the spinal cord,
brainstem, cerebellum, cerebrum,
hypothalamus and thalamus, was the major
replication site for the virus.
35
i.s.: intraspinal; i.v.: intravenous; i.c.: intracranial/intracerebral; i.t.: intratracheally; i.p.: intraperitoneal; s.c.: subcutaneous.
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cles are formed on the limbs and in the mouths of 1- to
1.5-month-old neonatal rhesus monkeys after EV71 in-
fection through the intratracheal route [9]. Both the
brown adipose tissue and skeletal muscle of the infected
monkeys contain large amounts of virus, which suggests
that these tissues are the primary target sites of viral
replication. Similar to that observed in adult rhesus
monkeys, the major inflammatory response is found in
the tracheas and lungs of the neonates. In contrast to
the cynomolgus monkeys, the typical neurological com-
plications, including flaccid paralysis and ataxia, are not
observed in the neonates, although both the medulla
oblongata and thalamus contain very high virus titers
and display neuropathological lesions. Additionally, the
monkeys do not display the clinical symptoms (i.e., ser-
ious encephalomyelitis and respiratory failure) that are
frequently present in severe human cases. Neonatal rhesus
monkeys seem to be a relevant model for EV71-induced
HFMD. Subsequent studies have shown that this neonatalmonkey model was feasible for evaluating the efficacy of
an inactivated EV71 vaccine [32].
b. Mouse models
b.1. Mouse-adaptation models In agreement with early
studies [12,13], we confirmed that neonatal mice are sus-
ceptible to an EV71 clinical isolate (EV71/Tainan/4643/98,
GenBank accession number AF304458) [33]. In the course
of the development of a mouse model for EV71, we real-
ized that the mice exhibited an age-dependent susceptibil-
ity to EV71 infection. Mice older than 14 days of age were
resistant to infection with EV71 clinical isolates regardless
of the inoculation route. Specifically, neither symptoms
nor mortality were observed in the 3- to 6-week-old
BALB/c, C3H/HeN or ICR mice after inoculation with the
EV7/4643 strain (4.7 × 109 pfu/ml; via through intracra-
nial, intravenous, intraperitoneal, or oral routes; Y. F.
Wang and C. K. Yu, unpublished observation). This age-
dependent susceptibility to EV71 has been subsequently
confirmed in numerous mouse models [34-37].
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velop an oral infection model that is suitable for the study
of the pathogenesis of this disease and for vaccine devel-
opment, particularly live attenuated vaccines, we gener-
ated a mouse–adapted EV71 strain, i.e., EV71/MP4, after
four serial passages of the parental strain EV71/4643 in
mice. Strain MP4 (5 × 106 PFU/mouse) was capable of or-
ally infecting 7-day-old mice and resulted in rear limb par-
alysis (with massive and widespread necrotizing myositis)
and neuropathology (with neuronal loss and apoptosis) in
the spinal cord and brainstem prior to the death of the in-
fected mice [6,15]. Subsequent study [38] and our unpub-
lished observations demonstrated that the mouse-adapted
EV71/MP4 strain displayed strong neurotropism and was
capable of consistently infecting and producing diseases
that included brain infection, flaccid paralysis, pulmonary
dysfunction and death in mice up to 14 days of age follow-
ing intraperitoneal, intramuscular, intracranial, or oral
inoculation. Furthermore, by observing the lag time of
the disease progression between the distal and proximal
viral inoculations via the use of colchicine, a fast axonal
transport inhibitor, we demonstrated that retrograde
axonal transport in neuron cells, but not hematogenous
transport, might be the major transmission route of
EV71 in mice [38]. This assumption has been supported
by other studies that have used both mice [34,39] and
rhesus monkeys [9].
This mouse-adapted EV71 model also allowed us to dis-
cover that type I interferon is an essential innate defense
mechanism that controls EV71 infection in mice [40] and
that EV71 per se inhibited the type I IFN system via the
3C protease while provoking a proinflammatory cytokine
response [41].
The mouse-adaption approach has been extensively
adopted by other investigators to develop infectious
models. Chua et al. [35] selected a mouse-adapted strain,
i.e., MP-26 M, after six passages of a cell-adapted clinical
isolate (CHO-adapted EV71-26 M) in newborn BALB/c
mice via intracranial inoculation. After intramuscular, in-
tracerebral or intraperitoneal challenge of the EV71/MP-
26 M, both 1- and 7-day-old BALB/c mice developed limb
paralysis with high tissue viral loads in the skeletal muscle.
Interestingly, this study again demonstrated that the VP1
mutation (G145E) alone was sufficient to increase the
virulence of this virus in mice. Our related studies re-
vealed that the substitution of three of the nucleotides of
EV71/MP4 in the 5′-NTR (C158U), VP1 (G145E), and
VP2 (K149M) regions were responsible for the increased
viral infectivity in vitro and the mouse virulence [6,42,43].
These results agree with those of Arita et al. [36] and
Chua et al. [35].
Similarly, Ong et al. [39] observed that EV71 could in-
duce encephalomyelitis in 2-week-old but not 4-week-old
ICR mice after inoculation with a mouse-adapted strainthat was isolated from 1-day-old mice after serial passage
of the virus in the brain tissue. The mouse-adapted EV71
strain was capable of infecting mice through both oral and
parenteral routes and was capable of entering the CNS via
peripheral motor nerves.
Wang et al. [44] isolated a mouse muscle-adapted
EV71 strain named Fuyang-0805a after four passages of
the parental EV71 strain in skeletal muscle. The Fuyang-
0805a strain exhibited strong myotropism and induced
severe necrotizing myositis in both skeletal and cardiac
muscles and induced intestinitis in 1-day-old ICR mice
after intraperitoneal infection. There were many muta-
tions in the genome of the muscle-adapted virus, includ-
ing VP1 (E145Q), which had previously been reported by
Chua et al. [35] and Huang et al. [43].
Arita et al. [36] took another approach to generating
mouse-adapted EV71 strains in adult immunodeficient
mice, which theoretically involved less selective pressure
on the virus. The EV71(NOD/SCID) strain was isolated
after three passages of the parental virus in the brains of
3-week-old NOD/SCID mice and caused paralysis in 3- to
4-week-old NOD/SCID mice. The adapted virus con-
tained a single amino acid substitution in the VP1 region
of EV71 (G145E) that was found to be essential for the
mouse-adapted phenotype in NOD/SCID mice. Likewise,
Caine et al. [45] generated mouse-adapted EV71 strains in
adult immunodeficient A129 (α/β IFN receptor deficient)
and AG129 (both α/β and γ IFN receptor deficient) mice.
The resulting virus was highly lethal to 10-week-old
AG129 mice and exhibited 100% lethality; the animals de-
veloped clinical symptoms that included limb paralysis,
eye irritation and loss of balance before death. It would be
worthwhile to know whether this adapted virus also ac-
quired increased virulence for immunocompetent mice.
To overcome the bias of the natural tropism of mouse-
adapted/muscle-adapted strains, Khong et al. [34] success-
fully infected 2-week-old AG129 mice with a non-mouse
adapted EV71 strain (a clinical isolate termed 5865/SIN/
00009). In these immunodeficient mice, the virus ex-
hibited strong neurotropism and induced neurological
manifestations after intraperitoneal and oral routes of
inoculation. Basically, this model exhibited features that
closely resemble those of the murine models that had pre-
viously been reported, including clinical manifestations,
tissue tropism, and histopathological changes. Collectively,
the defect of the IFN system may debilitate the application
of this model for the study of disease mechanisms, as alpha
IFN is an essential innate defense mechanism for control-
ling EV71 in mice [40], and defects in beta IFN signaling
(type II IFN) may alter the EV71-induced immunopatho-
genesis observed in immunocompetent hosts [41].
Yao et al. [46] experimentally infected 21-day-old gerbils
(Meriones unguiculatus) with an EV71 clinical isolate
(EV71/58301, C4 genotype) via intraperitoneal inoculation.
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histopathological abnormalities that were similar to those
that have been reported in the mouse models.b.2. Transgenic mouse models Viral receptors deter-
mine the host ranges and tissue-specific tropisms of en-
terovirus [47]. Two human receptors for EV71 were
identified in 2009: the human P-selectin glycoprotein
ligand-1 (PSGL-1, CD162) [48], and the human scavenger
receptor class B, member 2 (SCARB2) [49]. PSGL-1 is a
sialomucin membrane protein that is expressed exclu-
sively by myeloid and lymphoid white blood cells and
platelets and has a major role in the early stages of inflam-
mation. SCARB2 is also known as lysosomal integral
membrane protein II or CD36b-like-2. SCARB2 is local-
ized mainly to lysosomes and is widely expressed in many
human tissues and cell types. Additionally, sialyated gly-
cans [50] and annexin II [51] have also been reported to
be candidate receptors for EV71. Given the success of
poliovirus receptor transgenic mice in studies of poliovirus
pathogenesis and vaccine efficacy, transgenic mice ex-
pressing EV71 receptors have been actively developed.
Liu et al. [52] established a transgenic mouse line that
expresses the human PSGL-1 gene. However, these ani-
mals are only susceptible to a mouse muscle-adapted
EV71 strain and not to EV71 clinical isolates, and these
animals exhibited severe symptoms that are comparable
to those of wild-type mice upon EV71 infection. Given
that PSGL-1 is expressed by the dendritic cells in lymph
nodes and macrophages in the intestinal mucosa [53],
which are the primary sites of EV71 replication, it has
been speculated that human PSGL-1 might act as a cofac-
tor in the early stage of EV71 infection and that human
PSGL-1 alone is not sufficient to provoke the infectivity of
EV71 in mice. Indeed, clinical isolates have consistently
exhibited low binding affinities for PSGL-1.
Lin et al. [54] described a human SCARB2 transgenic
mouse line in which the molecule is expressed ubiqui-
tously. In these human SCRB2 transgenic mice, EV71 B
genotypes are associated with HFMD-like lesions (i.e.,
visible hair loss and scurf) and neurological disease that
include limb paralysis in 1-day-old mice but not in mice
older than 2 weeks of age. In contrast, 7- and 14-day-old
but not 21-day-old human SCARB2 transgenic mice are
more susceptible to the C genotypes of EV71 and coxsack-
ievirus A16, which are more likely to produce severe CNS
diseases, limb paralysis and death in these mice compared
to non-transgenic mice. Overall, the human SCARB2
transgenic mice have features that are similar to those of
the wild-type mouse models that have previously been re-
ported, including age-dependent susceptibility (only until
2 weeks of age), primarily viral replication sites in the
muscle and CNS and pathological changes.Fujii et al. [37] generated transgenic mice that express
the human SCARB2 with an expression profile that is
similar to that of humans (i.e., CNS neurons, lung pneu-
mocytes, hepatocytes and intestinal epithelium). The
human SCARB2 transgenic mice older than 6 weeks of
age are susceptible to infection by EV71 clinical isolates
and coxsackievirus A16, which use SCARB2 as a recep-
tor after intracranial, intravenous, intraperitoneal, and
intra-gastric inoculations. The mice display EV71 neuro-
tropism, neuropathology and clinical features (i.e., ataxia,
paralysis and death) that are similar to those displayed by
humans, monkeys and wild-type mice. The non-neuronal
tissues do not contain EV71 antigens or exhibit patho-
logical changes, such as pulmonary edema and cutane-
ous lesions. However, EV71 antigens and cutaneous
lesions have been noted in 1-day-old transgenic mice
after infection.
Pulmonary edema and the subsequent rapid onset of
cardiopulmonary failure are hallmarks of EV71-induced
mortality [55]. Unfortunately, none of the mouse models,
either the transgenic or non-transgenic models, exhibit
pulmonary edema, although CNS neuropathology, mus-
cular lesions, paralysis and death occur consistently fol-
lowing neuroinvasion. The absence of pulmonary edema
limits the applicability of these murine models to the
study of the disease mechanism of EV71.
Several reasons may explain why pulmonary edema is
absent in EV71-infected mice. First, EV71-infected mice
display a cytokine profile that is distinct from that of hu-
man patients, and the human cytokine profile may be es-
sential for the formation of pulmonary edemas [56].
Second, the nucleus tractus solitarii (NTS), an area known
to contribute to the development of pulmonary edema in
rats following injury [57,58], is not the CNS target of
EV71 infection in mice. Third, over-activation of the sym-
pathetic nervous system may be required for the develop-
ment of classic pulmonary edema symptoms, which may
be absent in the mouse models [59].
Animal models for testing vaccines and therapeutics
a. Vaccines
Both live attenuated and inactivated whole virus vaccines
have achieved successful control of poliovirus [60]. Thus,
it is logical to believe that EV71, which is similar to polio-
virus, can also be controlled with by vaccination. The fact
that passive transfer of specific antiserum provides protec-
tion against EV71 lethal challenge clearly illustrates not
only the important role of humoral immunity in the con-
trol of EV71 but also the feasibility of vaccination [33].
Several EV71 vaccine candidates, including live-attenuated
virus [30], inactivated whole virus [33,54,61-64], recom-
binant viral protein [65-67], virus-like particles and DNA
vaccines [66,68,69], have been developed, and their immuno-
genicity and efficiency have been evaluated in animal models.
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EV71, both mice and rhesus monkeys have demonstrated
the same immunogenicity (in terms of neutralization of
antibody titers and specific CD8+ T cell responses) elicited
by EV71 vaccine candidates [61]. Furthermore, it is tech-
nically feasible to assess the efficiency of inactivated vac-
cines in both animal species using distinct indicators,
i.e., survival rates (mice), pathology (monkeys) and tissue
viral loads (monkeys).
Given the age-dependent susceptibility to EV71 of la-
boratory mice, the EV71 vaccine candidates have primarily
been tested using maternal immunization in which the
dams are immunized before or during pregnancy, and
the newborn pups receive lethal challenges after delivery.
The efficacy of a formalin-inactivated whole-virus vac-
cine was first demonstrated in this setting as it pro-
longed the survival of pups after EV71 lethal challenge
[33]. Subsequently, this strategy had been applied to the
testing of other vaccine formulations [70-72].
Using an oral infection model, for the first time, we
proved the concept that live vaccines are feasible for pro-
tection against EV71 [73]. In our hands, oral infection
(intra-gastric challenge with mouse-adapted EV71 strains)
only worked in mice that were 7 days old or younger. Des-
pite this short time frame for immunization, we were able
to demonstrate that 1-day-old mice were tolerant of an
avirulent EV71 strain and mounted both systemic and
mucosal antibody responses with neutralizing activities.
More importantly, live EV71 active immunization at 1 day
of age reduced the mortality of the mice following lethal
challenge at 7 days of age. The same strategy had been ap-
plied to the testing of the efficacy of other live and inacti-
vated EV71 vaccine candidates [54] and to examination of
the therapeutic potential of a neutralizing antibody based
on neonatal human SCARB2 transgenic mice [74].
Our related study showed that whole body exposures
to EV71 viral suspension are an effective and less stressful
alternative for inducing the lethal infection of newborn
mice via the oral route [75]. In laboratory mice, fecal-oral
transmission of EV71 between infected and non-infected
littermates occurs after close contact [6,15]. Systemic in-
fection of neonate rhesus monkeys has also been noted
following intranasal inoculation with stool specimens
from EV71-infected monkeys [9].
Non-human primates have also been used to test the
immunogenicity and immunoprotection of potential EV71
vaccine candidates [32,61,68]. Macaque monkeys develop
both specific humoral and cellular immune responses to
both an inactivated EV71 vaccine and an EV71 virus-like
particle (VLP) vaccine [68]. However, challenge experi-
ments have not been performed to evaluate the efficacies
of these vaccine candidates. Chen et al. [32] reported that
neonatal (1.5-month-old) rhesus monkeys that are intra-
muscularly immunized with a formalin-inactivated, alum-based EV71 vaccine exhibit repressed viral-induced in-
flammatory reactions in the CNS and reduced IL-6, IFN-γ,
and TNF-α production. Adult rhesus monkeys that are
immunized with the inactivated vaccine also exhibit
good humoral and cellular immune responses and re-
duced pathologies and tissue viral loads upon live virus
challenge [61].
Antibody-related reactions, i.e., antibody-dependent en-
hanced infection [76,77] and antibody-mediated cytotox-
icity [78], may represent a safety concern for vaccine
development. Ch’ng et al. [78] demonstrated that the ab-
sence of EV71-neutralizing antibodies in the cerebrospinal
fluid of vaccine-immunized and EV71-challenged mon-
keys, which implies that antibody-mediated responses
might not be an issue, at least in monkeys.
b. Therapeutics
EV71 mouse models had been employed to test the anti-
EV71 activities of drugs that were originally developed
against human rhinoviruses and polioviruses, including
pleconaril [79,80], ribavirin [34,79,81] and rupintrivir
[82]. The efficacies of interferon-α [40,83] and interfer-
ing RNAs (siRNAs) [84] in inhibiting viral replication
have also been examined in this setting. Generally, these
anti-viral interventions exhibit certain protective or thera-
peutic effects when given either before or after EV71 in-
fection that include reductions in morality and tissue virus
loads and the alleviation of lesions. As susceptibility to
EV71 is age dependent, only neonatal mice can be effect-
ively infected. Thus, if an adult model were available, in-
creasing the dosage and the number of treatments would
improve the efficacy of the antiviral drugs.
Lactoferrin is a glycoprotein that is present in external
secretions of mammals, such as breast milk, tears, saliva
and mucous secretion [85]. Studies have demonstrated
that lactoferrin can inhibit EV71 infection by blocking
the absorption or receptor-mediated binding of the virus
to the target cells [86,87]. Chen et al. [88] generated a
transgenic mouse that expressed the porcine lactoferrin
in milk. Interestingly, four-day-old lectoferrin transgenic
mice are resistant to EV71 lethal challenge. This finding
raises the possibility of developing transgenic cows or
goats for the mass production of lactoferrin-enriched
milks and provides an evidence base that encourages
breast-feeding in humans.
Conclusion
None of the monkey or mouse EV71 models that have
been developed thus far recapitulate all of the aspects of
the human disease; some of these models lack face valid-
ity (i.e., resemblance to human symptoms) and others
lack construct validity (i.e., similarity to the underlying
cause of the human disease). The limited studies that have
been conducted in non-human primates have shown a
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in terms of tissue tropisms, primary viral replication
sites and disease manifestations. In general, the non-
human primate models are suitable for studying the
course of EV71 systemic infection. Indeed, these studies
using monkey models have advanced our knowledge of
the transmission modes and routes, clinical manifesta-
tions, pathologies, viral distributions, and immune re-
sponses related to EV71 infection, and these factors are
impossible to directly observe in human patients. Add-
itionally, monkeys seem to be better suited than mice
for evaluating the immunogenicity of EV71 vaccine can-
didates and are feasible for use in vaccine challenge tests
that use indicators other than those used in the mouse
models.
It is still unknown whether monkey EV71 neuroviru-
lence tests will be valuable as quantitative and sensitive
methods for detecting neurovirulent variants in live atten-
uated vaccine products because all of the EV71 genotypes
and genogroups that have been tested are neuroviru-
lent to cynomolgus monkeys. Furthermore, monkey
systems would most likely be replaced by EV71 receptor-
transgenic mice model when such models become
available.
No adult mouse model with full validity has been estab-
lished so far. Although adaptation would increase the
mouse virulence of the EV71 clinical isolates, the mouse-
adapted viruses themselves are unable to infect immuno-
competent mice beyond weanling age. Although older
immunodeficient mice (i.e., young adults) are susceptible
to the adapted viruses derived from immunodeficient
hosts, pulmonary edema has never been observed. More-
over, the strong myotropism of the mouse-adapted virus
would definitely alter the role of virus-related neuropath-
ology in the disease mechanism. Despite these shortcom-
ings, neonatal mouse models with mouse-adapted viruses
have contributed significantly to the study of EV71 in-
fection [38] and vaccine development [89]. More effort
should be applied to creating adult mouse models with
non-mouse adapted strains. These types of model will
provide better systems with longer age time frames for the
induction of the disease and/or immunization.
Human PSGL-1 transgenic mice are far from practical.
PSGL-1 is not expressed in neurons, which are the cellular
target of EV71; thus, these transgenic mice only acquiring
a transient infection of the gastrointestinal tract. Young
adult human SCARB2 transgenic mice (up to 6 weeks of
age) seem to be more vulnerable to the virus; however,
EV71-infected mice do not express the complete set of
human symptoms nor do they exhibit a disease mechan-
ism that is similar to the underlying cause of the human
disease. In theory, the identification of all of the human
EV71 receptors and co-receptors and the generation of
transgenic mice that express all of these receptors arecrucial to EV71 research and vaccine development. The
transgenic system represents a promising approach to cre-
ate relevant models of EV71.
The increased size and frequency of EV71 outbreaks
that have occurred over the past 16 years in the Asia-
Pacific region have caused serious public health concerns.
Fortunately, an inactivated EV71 vaccine has already
undergone a phase III clinical trial in China [90]. Although
an effective vaccine is expected in the near future, many
questions regarding the nature and host response of the
virus must be resolved, as these factors may compromise
the safety of the vaccine. These issues include viral evolu-
tion and recombination [91,92] and antibody-mediated re-
actions [76-78]. Appropriate animal models with full
validity are indispensable for answering these questions
and providing a better system for vaccine and drug
development.
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